Riskpilot← Back to searchSign inGet full accessZuLa Diagnostics AB
ABIn liquidationOrg 5568868854Manufacture of pharmaceutical preparations · NACE 2120Est. 20120 employees
Revenue 2023
SEK 0
EBITDA margin
—
-13802% vs 2022
Equity ratio
100.0%
Financial strength
Net profit 2023
SEK -218K
-16086% vs 2022
| Revenue | SEK 0 | — |
| EBITDA | SEK -189K | -13802% |
| Net profit | SEK -218K | -16086% |
| Total assets | SEK 59K | -79% |
| Equity | SEK 59K | -79% |
| Employees | 0 | — |
Legal name
ZuLa Diagnostics AB
Org number
5568868854
Legal form
Aktiebolag
NACE code
2120 · Manufacture of pharmaceutical preparations
Founded
6 mars 2012
Share capital
SEK 67 214
Employees
0
VAT registered
No
Audit selected
No
Last report
2023-12-31
Financial year
January – December
Signatory rights
Firman tecknas ensam av likvidatorn
Company purpose
Bedriva kontraktsanalys (CRO), läkemedelsutveckling, utveckla kosmetiska produkter, utveckla medical devices, bedriva forskning, utveckling, marknadsföring och försäljning av biotekniska instrument, processer, läkemedel, kosmetika, mjukvaror och patent, bedriva bioteknisk konsultverksamhet samt handel med fastigheter och värdepapper.
Address
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Revenue | 100 | 0 | 0 | 0 | 0 |
| Staff expenses | — | — | — | — | −1 |
| EBITDA | 70 | −16 | −3 | −1 | −189 |
| Depreciation & amort. | −0 | −0 | −0 | — | — |
| EBIT | 70 | −16 | −3 | −1 | −189 |
| Net financials | −2 | −1 | — | 0 | −28 |
| Profit before tax | 68 | −17 | −3 | −1 | −218 |
| Tax | −0 | −0 | −0 | — | — |
| Net profit | 68 | −17 | −3 | −1 | −218 |
| Item | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Total assets | 368 | 382 | 277 | 276 | 59 |
| Equity | 297 | 280 | 277 | 276 | 59 |
| Long-term debt | 0 | 0 | 0 | — | — |
| Short-term debt | 71 | 102 | 0 | 0 | 0 |
| Total debt | 71 | 102 | — | — | — |
EBITDA margin
-18906900.0%
This company
15.8%
Market median
-119664024% vs market
20192023
Equity ratio
100.0%
This company
38.2%
Market median
+162% vs market
20192023
Return on equity
-371.8%
This company
18.4%
Market median
-2121% vs market
20192023
Net profit margin
-21754000.0%
This company
8.1%
Market median
-268568001% vs market
20192023
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20192023
Debt / equity
0.00×
This company
0.62×
Market median
+100% vs market
20192023
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
CM Liquidator | Liquidator | 2022 |
| Name | Role | Member since |
|---|---|---|
| Former (1) | ||
| Deputy Board Member | 2022 – 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of ZuLa Diagnostics AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Carl Mårten Otto Wanning | Liquidator | 0 companies |
| Marina Zoubareva | Deputy Board Member | 0 companies |